According to a survey conducted among U.S. and Canadian pharmaceutical executives the major challenge for companies during the coronavirus pandemic is engaging and retaining patients for clinical trials. Another big challenge is the lack of time for patient education about studies.

According to a survey conducted in May 2020 in Italy, nearly ** percent of biotech companies operating in the health and pharmaceutical sector in the country were taking part in research and development (R&D) or production activities in the fight against the novel coronavirus disease (COVID-19).

The coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization. Read More

According to a survey conducted in March 2021 among U.S. adults, around ** percent of respondents stated that they either strongly approve or somewhat approve of how pharmaceutical companies handled the development of the COVID-19 vaccinations. This statistic illustrates the percentage of U.S. likely voters who approve of how pharmaceutical companies handled COVID-19 vaccine development.

The highly contagious SARS-CoV-2 virus, which causes coronavirus disease 2019 (COVID-19), emerged at the close of 2019 and has led to a medical crisis across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. Read More

The global market for clinical treatments for COVID-19 experienced significant growth during the pandemic's peak (2019-2024), driven by urgent medical needs and substantial government funding for research and development. While the acute phase of the pandemic has subsided, the market continues to evolve, albeit at a moderated Compound Annual Growth Rate (CAGR). This sustained growth reflects the ongoing need for effective treatments to manage long COVID, prevent severe illness in vulnerable populations, and prepare for potential future outbreaks. The market is segmented based on treatment modality (antivirals, monoclonal antibodies, immunotherapies, etc.), administration route (oral, intravenous, etc.), and patient population (adults, children, immunocompromised). Key players like Moderna, Pfizer, and Janssen Pharmaceuticals have established themselves, but the landscape is also characterized by the presence of smaller biotech companies, fostering innovation and competition in developing novel therapies. The market's future trajectory is influenced by factors such as the emergence of new COVID-19 variants, advancements in antiviral and immune-modulating therapies, evolving healthcare policies, and sustained investment in pandemic preparedness. The sustained growth in the COVID-19 treatment market is projected to continue, albeit at a slower pace than the initial surge. Factors like the development of new variants, the need for broader access to treatment in lower-income countries, and ongoing research into long COVID-related complications are all contributing to the continued market demand. The market's structure is likely to see increased consolidation as larger pharmaceutical companies acquire smaller biotech firms with promising treatment pipelines. The focus is shifting from emergency response to long-term management and preventive strategies, suggesting a move towards a more sustainable market based on prevention, early intervention, and targeted therapies. The success of future market growth will heavily depend on the successful development and widespread adoption of therapies that address the evolving challenges presented by the virus and its long-term effects.

The market for specific antiviral drugs targeting COVID-19 experienced significant growth during the pandemic's initial phases, driven by urgent global healthcare needs. While the initial surge has subsided with the widespread rollout of vaccines and the emergence of less virulent variants, the market remains substantial and is expected to evolve. We estimate the 2025 market size to be approximately $2.5 billion, reflecting a post-pandemic stabilization. This figure takes into account the reduced immediate demand while acknowledging ongoing needs for treatment of severe cases and potential future outbreaks or the emergence of new variants requiring specific antiviral therapies. A compound annual growth rate (CAGR) of 5% is projected for the forecast period of 2025-2033, indicating sustained, albeit more moderate, market growth fueled by ongoing research and development efforts focused on improving existing antivirals and developing novel therapeutics. This moderate growth reflects a shift from emergency procurement to a more stable, albeit still considerable, demand. Factors influencing future market growth include the development of pan-coronavirus therapeutics, government policies regarding preparedness for future pandemics, and the prevalence of long COVID, which may require ongoing antiviral management. Major players like Sanofi, Novartis, and Teva, alongside significant contributions from Asian pharmaceutical companies such as Shanghai Zhongxisanwei, Zydus Cadila, and Sun Pharma, continue to shape the competitive landscape. The market is segmented based on drug type (e.g., nucleoside analogs, protease inhibitors), route of administration (oral, intravenous), and geographical region. Challenges include the potential for antiviral resistance and the need for continuous monitoring of evolving viral strains. Strategic partnerships, mergers and acquisitions, and ongoing clinical trials are key activities driving further market evolution. This market will likely see increased focus on preventative measures and broader-spectrum antiviral therapies capable of addressing future viral threats.

COVID-19 Therapeutics Market Outlook

According to our latest research, the global COVID-19 therapeutics market size reached USD 26.4 billion in 2024, reflecting a dynamic industry shaped by evolving virus variants, ongoing vaccination campaigns, and persistent demand for effective treatments. The market is projected to grow at a CAGR of 7.1% from 2025 to 2033, reaching an estimated USD 49.1 billion by 2033. This growth is primarily driven by the continuous emergence of new viral strains, rising investments in pharmaceutical research and development, and robust government support for pandemic preparedness and response initiatives. As per our analysis, the market’s upward trajectory underscores the critical role of therapeutics in complementing vaccination efforts and managing severe or breakthrough cases globally.

A central growth factor for the COVID-19 therapeutics market is the relentless evolution of SARS-CoV-2, which has led to the emergence of multiple variants with varying degrees of transmissibility and immune escape. These variants, including Omicron sub-lineages and others, have necessitated the development of new and more effective antiviral drugs, monoclonal antibodies, and immunomodulators. Pharmaceutical companies and research institutions are rapidly adapting their pipelines to address these challenges, resulting in a continuous influx of innovative therapeutics. Additionally, regulatory agencies have demonstrated unprecedented agility in approving emergency use authorizations and fast-tracking promising candidates, further accelerating market expansion. The demand for therapeutics remains strong, particularly for high-risk populations such as immunocompromised individuals, the elderly, and those with comorbidities.

Another significant driver is the global focus on pandemic preparedness and the strategic stockpiling of COVID-19 therapeutics by governments and health organizations. Many countries have established agreements with leading pharmaceutical companies to ensure timely access to vital medications in the event of new outbreaks or surges. This proactive approach not only stabilizes supply chains but also incentivizes ongoing research and development. Furthermore, the integration of COVID-19 therapies into standard treatment protocols for respiratory illnesses has expanded the market’s scope, as clinicians increasingly prescribe these drugs for patients presenting with severe or prolonged symptoms. The market is also benefitting from collaborations between public and private sectors, which have led to the co-development of novel formulations and combination therapies.

The widespread adoption of advanced drug delivery systems and the diversification of distribution channels have also played pivotal roles in market growth. Innovations in oral and intravenous formulations have improved patient compliance and broadened the range of therapeutic options available to healthcare providers. The expansion of hospital, retail, and online pharmacies has facilitated greater accessibility, particularly in regions with limited healthcare infrastructure. Additionally, the growing trend toward homecare and outpatient management of mild-to-moderate COVID-19 cases has stimulated demand for user-friendly and easily administered therapeutics. This shift is supported by telemedicine platforms and digital health tools that enable remote monitoring and prescription fulfillment, further enhancing the market’s reach.

Regionally, North America continues to dominate the COVID-19 therapeutics market, accounting for the largest revenue share in 2024, followed closely by Europe and the Asia Pacific. The United States, in particular, benefits from a robust pharmaceutical industry, substantial government funding, and high rates of therapeutic adoption. Europe’s market is driven by strong regulatory frameworks and cross-border collaborations, while the Asia Pacific region is experiencing rapid growth due to rising healthcare investments and increasing disease awareness. Latin America and the Middle East & Africa are emerging as important markets, supported by international aid and expanding healthcare infrastructure. Each region faces unique challenges and opportunities, shaping the overall landscape of COVID-19 therapeutics.

Drug Class Analysis

The COVID-19 therapeutics market is segmented by drug class into antiviral drugs, immunomodulators, monoclonal antibodies, corticosteroids, and others. Among these, antiviral d

The sample is drawn from the Industrial R&D Investment Scoreboard published by the IRI/JRC, which tracks the world’s top 1000 firms by R&D spending. Chinese and EU-based pharmaceutical companies form a significant portion of the dataset, making it well-suited for a DID design to compare post-COVID changes in R&D investment across regions. The dataset was restructured into a panel of firm-year observations from 2015 to 2024, covering key variables such as R&D input, capital expenditure, profit, and employment. After excluding entries with missing values in core variables, standard data-cleaning procedures using Stata was implemented. The final analytical sample includes 217 firms, covering 114 Chinese and 103 EU companies, observed over an unbalanced panel structure. Company identity is tracked via the company variable. Key financial indicators such as R&D input, profits, and employees exhibit variation across both time and geography, justifying a panel-data approach.

The COVID-19 treatment market experienced explosive growth during the pandemic's initial phases, driven by the urgent need for effective therapies. While the acute phase of the pandemic has subsided, a significant market remains, fueled by the ongoing need for treatments for long COVID, the emergence of new variants, and the potential for future pandemics. The market size in 2025 is estimated at $15 billion, reflecting a continued demand for antiviral medications, antibody therapies, and supportive care treatments. A compound annual growth rate (CAGR) of 8% is projected from 2025-2033, driven by advancements in therapeutics, including the development of novel antivirals with improved efficacy and reduced side effects, as well as the expansion of access to these treatments in developing nations. Key segments within the market include antiviral drugs (e.g., Paxlovid), monoclonal antibodies, and other supportive care medications. Major players like Moderna, Pfizer, and Johnson & Johnson continue to dominate, while smaller biotech firms are also actively involved in research and development, contributing to the innovation pipeline. Market restraints include the potential for drug resistance, the high cost of some treatments, and the ongoing need for equitable access to effective therapies globally. The future of the COVID-19 treatment market will be shaped by several factors. Continued research and development will be crucial in developing more effective and accessible treatments for long COVID and emerging variants. The market will likely see increased consolidation as larger pharmaceutical companies acquire smaller biotech firms with promising technologies. Government funding and public-private partnerships will play a significant role in accelerating innovation and ensuring equitable global access. The market will also witness a shift towards preventative measures, including advanced vaccines and improved surveillance systems, to mitigate future outbreaks. The long-term sustainability of the market will depend on successfully transitioning from an emergency response to a more sustainable, proactive approach to pandemic preparedness. Pricing strategies and reimbursement policies will also play a pivotal role in determining the market's overall trajectory.

Read More

Discover the latest market analysis on antiviral drugs for COVID-19. Explore market size, CAGR, key players (Sanofi, Novartis, etc.), regional trends, and future growth projections from 2025 to 2033. This in-depth report reveals insights into the evolving landscape of COVID-19 treatments and the ongoing demand for effective antiviral therapies.

The coronavirus pandemic has affected the entire world and many families have been destroyed. The stock exchange was also affected, but vaccine companies took advantage of this moment and leveraged their profits

Biotech companies:

• PFIZER: Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas.

• ASTRAZENECA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• BIONTECH: BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

• MODERNA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• NOVAVAX: Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases.

Check the movement of the financial market through this dataset

Use your creativity and external information

Snapshot img { margin: 10px !important; } This pipeline analysis report provides detailed insights into the clinical trials landscape of COVID-19 therapeutics, including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration (RoA), target, mechanism of action (MoA), and therapeutic modalities. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline molecules for COVID-19 including AbbVie Inc., AIM ImmunoTech Inc., Ansun BioPharma, APEIRON Biologics AG, Ascletis Pharma Inc., Blade Therapeutics Inc., Can-Fite BioPharma Ltd., CanSino Biologics Inc., Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd., FUJIFILM Corp., Gilead Sciences Inc., IMV Inc., InflaRx GmbH, Inovio Pharmaceuticals Inc., and Johnson & Johnson Services Inc.

Overview of Therapeutic Pipeline for COVID-19

The COVID-19 pandemic started in China in the last quarter of 2019 and spread globally by early 2020. Globally, the incidence and prevalence of COVID-19 are increasing aggressively. According to the Worldometers.info report, updated on April 13, 2020, the number of COVID-19 cases reported was 1,862,254, out of which 6.17% of the people have lost their lives, and about 23.18% people have been recovered globally.

Coronavirus disease (COVID-19) is infectious and is caused by a new coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the people affected with COVID-19 experience mild-to-moderate respiratory illness and recover without requiring special treatment. However, older people and people with certain medical conditions, including cardiovascular diseases, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness. Currently, there are no specific vaccines or treatments for COVID-19. However, owing to the above-mentioned factors, many ongoing clinical trials are evaluating potential treatments, especially target molecules for the immune system. Over 26% of the molecules in the pipeline are currently in the pre-clinical stages.

Companies covered

Several companies are involved in the development of pipeline molecules for COVID-19. In addition to the companies, major institutes, universities, and hospitals are also conducting studies on COVID-19. Moreover, companies are collaborating with institutions such as the US Department of Health & Human Services and the University of British Columbia to use the available technologies properly for the further development and commercialization of molecules.

The report covers detailed information on several companies actively involved in the development of molecules for COVID-19 including -

AbbVie Inc.
AIM ImmunoTech Inc.
Ansun BioPharma
APEIRON Biologics AG
Ascletis Pharma Inc.
Blade Therapeutics Inc.
Can-Fite BioPharma Ltd.
CanSino Biologics Inc.
Clover Biopharmaceuticals
F. Hoffmann-La Roche Ltd.
FUJIFILM Corp.
Gilead Sciences Inc.
IMV Inc.
InflaRx GmbH
Inovio Pharmaceuticals Inc.
Johnson & Johnson Services Inc.
Mallinckrodt Plc
Moderna Inc.
NeuroRx Inc.
Novavax Inc.
OncoImmune Inc.
OyaGen Inc.
Pulmotect Inc.
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals Inc.
Sanofi
SLA Pharma AG
Sorrento Therapeutics Inc.
Swedish Orphan Biovitrum AB
Symvivo Corp.
Takeda Pharmaceutical Co.
Tonix Pharmaceuticals Holding Corp.
Vanda Pharmaceuticals Inc.
Vaxart Inc.

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Route of Administration

Oral
Intravenous
Nasal
Intradermal
Intramuscular
Unknown

Most of the pipeline molecules for COVID-19 treatment are being developed for oral administration. Additionally, companies and institutions are also focusing on developing drugs that can be delivered through the subcutis (intravenous RoA).

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Therapy

Monotherapy
Combination therapy

Monotherapy uses a single drug to treat a disorder. Over 64% of the molecules that are currently in the pipeline to treat COVID-19 are being developed as monotherapy drugs.

COVID-19 - Pipeline Analysis: Key Highlights of the Report

What are the therapy molecules used in the various development stages of COVID-19?
What are the companies that are currently involved in the development of therapeutic molecules for COVID-19?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule

We can help! Our analysts can customize this report to meet your requirements. Get in touch

COVID-19 Therapeutics Market Outlook

According to our latest research, the global COVID-19 therapeutics market size reached USD 46.7 billion in 2024, driven by the ongoing need for effective treatment options amidst evolving variants and persistent global outbreaks. The market is projected to expand at a CAGR of 7.2% from 2025 to 2033, reaching an estimated USD 87.1 billion by 2033. This robust growth is primarily fueled by continuous innovation in drug development, increased government initiatives, and a strong pipeline of therapeutic candidates targeting COVID-19 and its complications.

One of the primary growth drivers for the COVID-19 therapeutics market is the relentless pace of research and development activities. Pharmaceutical companies and research institutions worldwide have accelerated their efforts to develop new antiviral drugs, monoclonal antibodies, and immunomodulators tailored to combat SARS-CoV-2 and its emerging variants. The rapid mutation of the virus has necessitated the ongoing adaptation and improvement of therapeutics, prompting significant investments in clinical trials and regulatory approvals. Additionally, the collaboration between public and private sectors has expedited the introduction of innovative treatment solutions, which has further strengthened the market’s growth trajectory.

Another significant factor contributing to market expansion is the rising prevalence of severe COVID-19 cases, particularly among high-risk populations such as the elderly and immunocompromised individuals. The burden on healthcare systems has led to an increased demand for effective therapeutics that can reduce hospitalization rates, minimize mortality, and improve patient outcomes. As new variants continue to emerge, the need for broad-spectrum and variant-specific treatments remains critical. This ongoing demand has encouraged the development of combination therapies and repurposing of existing drugs, further diversifying the market landscape and ensuring a steady flow of novel therapeutics.

Governmental support and favorable regulatory frameworks have also played a pivotal role in market growth. Regulatory agencies such as the FDA, EMA, and WHO have implemented fast-track approval processes and emergency use authorizations, allowing for the swift deployment of promising therapeutics. Substantial funding and procurement agreements from governments and international organizations have ensured widespread access to essential medicines, particularly in low- and middle-income countries. This proactive approach has not only helped manage the pandemic more effectively but has also stimulated further investment in the research and commercialization of COVID-19 therapeutics.

From a regional perspective, North America continues to dominate the COVID-19 therapeutics market, followed closely by Europe and the Asia Pacific. The United States, in particular, holds a substantial share due to its advanced healthcare infrastructure, strong presence of key players, and high investment in R&D. Europe benefits from extensive government initiatives and a robust pharmaceutical sector, while the Asia Pacific region is witnessing rapid growth driven by increasing healthcare expenditure, rising awareness, and expanding access to therapeutics. Latin America and the Middle East & Africa are also experiencing steady growth, albeit at a slower pace, as they continue to enhance their healthcare capabilities and improve access to COVID-19 treatments.

Drug Class Analysis

The COVID-19 therapeutics market is segmented by drug class into antiviral drugs, monoclonal antibodies, corticosteroids, immunomodulators, and others. Antiviral drugs have been at the forefront of the market, owing to their direct action against the SARS-CoV-2 virus. Drugs such as remdesivir and molnupiravir have gained significant traction due to their ability to reduce viral replication and improve clinical outcomes in hospitalized patients. The ongoing development of next-generation antivirals, including those targeting new variants, is expected to

Over ** percent of the total revenue of the Russian pharmaceutical company R-Pharm came from sales of medicines for treatment of the coronavirus (COVID-19) in 2021. Furthermore, COVID-19 drug sales accounted for almost ** percent of the revenue of Pfizer in Russia.

The global market for specific antiviral drugs for COVID-19 is anticipated to reach approximately USD XXX million by 2033, exhibiting a CAGR of XX% from 2025 to 2033. The significant rise in COVID-19 infections, along with the increasing awareness and availability of specific antiviral drugs, is primarily driving market growth. Key market trends include the development of novel antiviral agents, strategic collaborations between pharmaceutical companies, and government initiatives to support research and development efforts. Geographically, North America is expected to hold a dominant market share due to the high prevalence of COVID-19 cases, well-established healthcare infrastructure, and rapid adoption of innovative therapies. Despite the promising advancements in specific antiviral drugs for COVID-19, certain restraints hinder market expansion. These include concerns over drug resistance, the potential for adverse drug reactions, and the need for continuous monitoring of drug efficacy against emerging viral variants. Moreover, the competitive landscape is characterized by the presence of both established pharmaceutical companies and emerging biotech firms, leading to intense competition and challenges in market penetration. Nonetheless, ongoing research and development efforts are expected to unlock new opportunities for the development of safe and effective antiviral drugs, driving sustained market growth in the long term. The report provides a comprehensive analysis of the market's key segments, regional dynamics, competitive landscape, and future prospects, offering valuable insights for stakeholders in the healthcare industry.

Discover the booming Oral COVID-19 Vaccine market, projected to reach $1224.9 million in 2025 with a 5% CAGR. Explore market trends, key players (Pfizer, CanSino Biologics, etc.), and regional analysis in this comprehensive report. Learn about tablet and inhalable types and their impact on global vaccination strategies.

Explore the dynamic market for coronavirus infection treatments, featuring insights on market size, CAGR, key drivers, and future trends. Discover leading companies and regional growth opportunities in this crucial healthcare sector.

COVID-19 Vaccines Market Outlook

According to our latest research, the global COVID-19 vaccines market size stood at USD 34.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but still underscoring the ongoing demand for booster shots, variant-specific formulations, and immunization programs. The market is expected to reach USD 14.7 billion by 2033, registering a compound annual growth rate (CAGR) of 9.8% over the forecast period. This trajectory is driven by persistent global immunization efforts, the emergence of new SARS-CoV-2 variants, and the integration of COVID-19 vaccines into routine vaccination schedules.

The primary growth factor for the COVID-19 vaccines market is the continued evolution of the SARS-CoV-2 virus, leading to the emergence of new variants. These variants often exhibit mutations that may partially evade immunity conferred by previous infection or vaccination, necessitating the development and deployment of updated vaccine formulations. Pharmaceutical companies are investing in next-generation vaccines, including multivalent and pan-coronavirus candidates, to address these challenges. Governments and health organizations remain vigilant, maintaining stockpiles and rolling out booster campaigns, especially for high-risk populations such as the elderly and immunocompromised. The integration of COVID-19 vaccines with seasonal influenza programs is also being explored, potentially driving market growth through combined immunization initiatives.

Another crucial driver is the growing emphasis on equitable vaccine access, particularly in low- and middle-income countries. International collaborations, such as COVAX and bilateral donation agreements, have played a vital role in expanding vaccine reach beyond high-income nations. As the acute phase of the pandemic subsides, there is a strategic shift towards sustained immunization efforts, with many countries incorporating COVID-19 vaccines into their national immunization schedules. This long-term approach is expected to stabilize demand and support market growth, albeit at a lower volume compared to the pandemic’s initial years. Additionally, the development of pediatric and variant-adapted vaccines is broadening the addressable market, ensuring ongoing relevance for manufacturers.

Technological advancements in vaccine platforms, particularly mRNA and protein subunit technologies, are reshaping the market landscape. The success of mRNA vaccines has spurred further research into their application for other infectious diseases, creating a pipeline of innovative products. These platforms offer advantages such as rapid adaptability to emerging variants and scalable manufacturing, making them attractive for both public health authorities and commercial stakeholders. The competitive environment is also fostering partnerships between pharmaceutical companies, biotechnology firms, and academic institutions to accelerate research and development. Such collaborations are expected to yield more effective and durable vaccines, further propelling the market’s evolution.

From a regional perspective, North America and Europe continue to lead the market in terms of revenue, owing to robust healthcare infrastructure, high vaccination coverage, and proactive government policies. The Asia Pacific region is witnessing the fastest growth, driven by large population bases, increasing healthcare investments, and expanding immunization programs. Latin America and the Middle East & Africa are gradually improving their vaccination rates, supported by international aid and local manufacturing initiatives. The regional dynamics are influenced by factors such as regulatory approvals, supply chain logistics, and public acceptance of vaccines, which collectively shape the market’s trajectory across different geographies.

Vaccine Type Analysis

The COVID-19 vaccines market is segmented by vaccine type into mRNA vaccines, viral vector vaccines, protein subunit vaccines, inacti